Login to Your Account

Teijin, Sigma-Tau ink orphan drug agreement in Japan

By Cornelia Zou
Staff Writer

Thursday, June 26, 2014
Japan´s Teijin Pharma Ltd. entered an exclusive development and sales agreement with Sigma-Tau Pharmaceuticals Inc. that will allow Teijin to participate in the development of EZN-2279, a therapeutic agent for adenosine deaminase (ADA) deficiency, as well as to distribute the final product in Japan.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription